Send to

Choose Destination

See 1 citation found by title matching your search:

Stroke. 2013 Dec;44(12):3580-3. doi: 10.1161/STROKEAHA.113.003226. Epub 2013 Oct 17.

Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study.

Author information

From the Department of Pharmacology, National University of Singapore, Singapore (C.L.H.C.); Raffles Neuroscience Centre, Raffles Hospital, Singapore (N.V.); Singapore Clinical Research Institute, Singapore (C.F.L.); Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories (K.S.L.W.); Lariboisière University Hospital, Paris, France (M.-G.B.).



Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset.


Post hoc analysis was performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study, a randomized, placebo-controlled, double-blinded trial that compared MLC601 with placebo in 1099 subjects with ischemic stroke of intermediate severity in the preceding 72 hours. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset.


The frequency of early vascular events during the 3-month follow-up was significantly less in the MLC601 group than in the placebo group (16 [2.9%] versus 31 events [5.6%]; risk difference=-2.7%; 95% confidence interval, -5.1% to -0.4%; P=0.025) without an increase in nonvascular deaths. Kaplan-Meier survival analysis showed a difference in the risk of vascular outcomes between the 2 groups as early as the first month after stroke (Log-rank P=0.024; hazard ratio, 0.51; 95% confidence interval, 0.28-0.93).


Treatment with MLC601 was associated with reduced early vascular events among subjects in the CHIMES study. The mechanisms for this effect require further study.

CLINICAL TRIAL REGISTRATION URL: Unique identifier: NCT00554723.


Neuroaid; clinical trial; secondary prevention; stroke; vascular diseases

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center